What if a machine could dream up and build new molecules faster than any human chemist? In 2025, Glasgow-based Chemify secured a $50 million Series B funding round to do exactly that—combining artificial intelligence with robotics to accelerate pharmaceutical molecule creation. As of April 2026, the company is scaling its platform to transform how drugs are discovered, promising to slash years off traditional development timelines. This article explores how Chemify’s AI-robotics chemistry platform works, why the funding matters, and what it means for the future of medicine.
Chemify’s $50M Series B: A Milestone for AI-Driven Chemistry
Announced in early 2025, Chemify’s Series B raise brought total investment to over $80 million. The round was led by prominent venture capital firms, including Horizons Ventures and existing backers, signaling strong confidence in the company’s vision. Chemify plans to use the funds to advance its AI platform and robotic systems, which automate the synthesis of novel molecules—a process traditionally reliant on slow, manual trial-and-error by chemists.
The Scottish startup, spun out from the University of Glasgow, aims to become the operating system for chemical discovery. By integrating machine learning with automated lab equipment, Chemify can design, test, and refine thousands of molecular candidates in parallel, a feat impossible for human teams alone.
How Chemify’s AI-Robotics Platform Works
From Digital Design to Physical Molecules
Chemify’s core technology is a “chemical computer” that uses AI algorithms to predict which molecular structures will have desired properties—such as binding to a disease target or being safe for human use. Once a candidate is selected, robotic arms and microfluidics systems synthesize the molecule in real time, with sensors providing instant feedback to the AI. This closed-loop system iterates rapidly, reducing the typical drug discovery cycle from years to months.
Key Components of the Platform
- AI Design Engine: Uses deep learning on chemical databases to propose novel molecules.
- Robotic Synthesis Lab: Automated reactors, purifiers, and analyzers that run 24/7.
- Data Feedback Loop: Every experiment updates the AI model, improving future predictions.
According to a 2025 whitepaper from Chemify, the platform can generate over 10,000 molecular variants per week, compared to a few dozen by traditional methods. This throughput is critical for tackling complex diseases like cancer and neurodegenerative disorders.
Funding Impact: Scaling Production and Partnerships
The $50 million injection is being deployed to expand Chemify’s facilities in Glasgow and hire top talent in AI, robotics, and chemistry. As of early 2026, the company has tripled its lab space and added a second robotic synthesis line. Additionally, Chemify has forged partnerships with major pharmaceutical firms, including a multi-year deal with a top-10 pharma company to co-develop candidates for oncology.
“We’re moving from proof-of-concept to industrial scale,” said a Chemify spokesperson in a 2025 press release. “This funding allows us to bring our platform to more partners and ultimately get life-saving drugs to patients faster.”
The Broader Trend: AI and Robotics in Drug Discovery
Chemify is part of a wave of startups using AI and automation to revolutionize pharma. Competitors like Recursion Pharmaceuticals and Insilico Medicine have also raised significant funding, but Chemify’s focus on physical synthesis sets it apart. While many AI platforms only predict molecules, Chemify actually builds them, bridging the gap between digital design and real-world chemistry.
A 2025 report from McKinsey estimated that AI-driven drug discovery could reduce R&D costs by up to 40% and shorten development timelines by 50% by 2030. Companies like Chemify are at the forefront, turning this potential into reality.
Challenges and Future Outlook
Despite its promise, Chemify faces hurdles. Scaling robotic labs is capital-intensive, and regulatory approval for AI-designed molecules remains uncharted territory. However, the company’s Series B success suggests investors are betting on long-term returns. Looking ahead to the rest of 2026, Chemify plans to launch a cloud-based version of its platform, allowing smaller biotechs to access its capabilities via subscription.
As the pharmaceutical industry increasingly embraces automation, Chemify’s blend of AI and robotics positions it as a key player in the next era of drug discovery. The molecules created today could become the therapies of tomorrow.
